Collegium Pharmaceutical (COLL) EPS (Weighted Average and Diluted) (2014 - 2026)

Collegium Pharmaceutical's EPS (Weighted Average and Diluted) history runs 11 years deep, the most recent figure standing at $0.4 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 471.43% year-over-year to $0.4; the TTM figure through Mar 2026 stood at $2.04 (up 67.21% YoY), while the FY2025 annual figure was $1.73, down 6.99% from the prior year.
• EPS (Weighted Average and Diluted) was $0.4 for Q1 2026 at Collegium Pharmaceutical, down from $0.46 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.84 in Q3 2025 to a low of -$0.51 in Q1 2023.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.26 across 5 years, with a median of $0.34 in 2023.
• The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) sank 195.12% in 2022, then surged 5200.0% in 2023.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.21 in 2022, then soared by 490.48% to $0.82 in 2023, then tumbled by 56.1% to $0.36 in 2024, then gained by 27.78% to $0.46 in 2025, then decreased by 13.04% to $0.4 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.4 (Q1 2026), $0.46 (Q4 2025), and $0.84 (Q3 2025), per Business Quant data.